Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mNSCLC - L2 - EGFR mutant, immune chekpoint inhibitors vs. gene alteration target therapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CAURAL (EXPLORATORY), 2019 2.60 [0.39; 17.16]
2.60 [0.39 ; 17.16 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable progression or deaths (PFS)detailed results CAURAL (EXPLORATORY), 2019 1.10 [0.22; 5.61]
1.10 [0.22 ; 5.61 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable objective responses (ORR)detailed results CAURAL (EXPLORATORY), 2019 0.45 [0.08; 2.40]
0.45 [0.08 ; 2.40 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable AE (any grade)detailed results CAURAL (EXPLORATORY), 2019 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 12.38 [1.29; 118.34]
12.38 [1.29 ; 118.34 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable AE leading to death (grade 5)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable SAE (any grade)detailed results CAURAL (EXPLORATORY), 2019 1.64 [0.32; 8.45]
1.64 [0.32 ; 8.45 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable STRAE (any grade)detailed results CAURAL (EXPLORATORY), 2019 0.33 [0.01; 10.81]
0.33 [0.01 ; 10.81 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable TRAE (any grade)detailed results CAURAL (EXPLORATORY), 2019 2.33 [0.41; 13.17]
2.33 [0.41 ; 13.17 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable TRAE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 7.08 [0.34; 148.71]
7.08 [0.34 ; 148.71 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Arthralgia AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Back pain AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Constipation AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Cough AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Diarrhoea AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 1.44 [0.04; 46.58]
1.44 [0.04 ; 46.58 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Dry skin AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Dyspnoea AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Nausea AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Neutropenia AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 3.07 [0.13; 74.70]
3.07 [0.13 ; 74.70 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Pneumonia AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 3.07 [0.13; 74.70]
3.07 [0.13 ; 74.70 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Pruritus AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Rash AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Stomatitis AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 01:11 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 204
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743